ImmunoCellular Therapeutics (IMUC) Enters Agreement with Novella on ICT-107 Phase 3 in Glioblastoma
Tweet Send to a Friend
ImmunoCellular Therapeutics (NYSE: IMUC) announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE